## Yu Rao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4481811/publications.pdf

Version: 2024-02-01

		147566	174990
53	3,224	31	52
papers	citations	h-index	g-index
54	54	54	3463
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	PROTACs: great opportunities for academia and industry. Signal Transduction and Targeted Therapy, 2019, 4, 64.	7.1	367
2	Pdâ€Catalyzed CH Oxygenation with TFA/TFAA: Expedient Access to Oxygenâ€Containing Heterocycles and Lateâ€Stage Drug Modification. Angewandte Chemie - International Edition, 2012, 51, 13070-13074.	7.2	253
3	PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Research, 2018, 28, 779-781.	5.7	215
4	Regio―and Chemoselective CH Chlorination/Bromination of Electronâ€Deficient Arenes by Weak Coordination and Study of Relative Directingâ€Group Abilities. Angewandte Chemie - International Edition, 2013, 52, 4440-4444.	7.2	175
5	PROTAC Technology: Opportunities and Challenges. ACS Medicinal Chemistry Letters, 2020, 11, 237-240.	1.3	169
6	Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. Journal of Medicinal Chemistry, 2019, 62, 7575-7582.	2.9	127
7	Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chemical Communications, 2019, 55, 369-372.	2.2	114
8	An Efficient Palladiumâ€Catalyzed CH Alkoxylation of Unactivated Methylene and Methyl Groups with Cyclic Hypervalent Iodine (I <sup>3+</sup> ) Oxidants. Angewandte Chemie - International Edition, 2013, 52, 13606-13610.	7.2	110
9	Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia, 2019, 33, 2105-2110.	3.3	105
10	Synthesis of 2-Aminophenols and Heterocycles by Ru-Catalyzed Câ€"H Mono- and Dihydroxylation. Organic Letters, 2013, 15, 2334-2337.	2.4	89
11	Developing potent PROTACs tools for selective degradation of HDAC6 protein. Protein and Cell, 2019, 10, 606-609.	4.8	89
12	A chemical approach for global protein knockdown from mice to non-human primates. Cell Discovery, 2019, 5, 10.	3.1	87
13	PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	77
14	Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nature Chemical Biology, 2021, 17, 567-575.	3.9	76
15	A diversity-oriented synthesis of bioactive benzanilides via a regioselective C(sp <sup>2</sup> )–H hydroxylation strategy. Chemical Science, 2016, 7, 2229-2238.	3.7	74
16	Regioselective Annulation of Aryl Sulfonamides with Allenes through Cobalt-Promoted C–H Functionalization. Organic Letters, 2017, 19, 972-975.	2.4	72
17	Plasticity in designing PROTACs for selective and potent degradation of HDAC6. Chemical Communications, 2019, 55, 14848-14851.	2.2	69
18	Cobalt-catalyzed C–H activation and regioselective intermolecular annulation with allenes. Organic Chemistry Frontiers, 2017, 4, 204-209.	2.3	62

#	Article	IF	CITATIONS
19	Weak Coordination Promoted Regioselective Oxidative Coupling Reaction for 2,2′-Difunctional Biaryl Synthesis in Hexafluoro-2-propanol. Organic Letters, 2015, 17, 4456-4459.	2.4	53
20	Global PROTAC Toolbox for Degrading BCR–ABL Overcomes Drug-Resistant Mutants and Adverse Effects. Journal of Medicinal Chemistry, 2020, 63, 8567-8583.	2.9	52
21	Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of <i>Plasmodium falciparum</i> ( <i>Pf</i> NDH2) with Small Molecule To Eliminate Drug-Resistant Malaria. Journal of Medicinal Chemistry, 2017, 60, 1994-2005.	2.9	51
22	Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs. ACS Medicinal Chemistry Letters, 2020, 11, 1855-1862.	1.3	50
23	Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 4056-4073.	2.9	49
24	PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance. Biochemistry, 2020, 59, 240-249.	1.2	47
25	A General Approach towards Catechol and Pyrogallol through Ruthenium―and Palladiumâ€Catalyzed Cĭ£¿H Hydroxylation by Weak Coordination. Advanced Synthesis and Catalysis, 2014, 356, 1625-1630.	2.1	44
26	Some recent advances in transition-metal-catalyzed ortho SP2 C-H functionalization using Ru, Rh, and Pd. Science China Chemistry, 2014, 57, 930-944.	4.2	42
27	Development of a Rhodium(II)â€Catalyzed Chemoselective C(sp <sup>3</sup> )H Oxygenation. Chemistry - A European Journal, 2015, 21, 14937-14942.	1.7	38
28	Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase. Journal of Medicinal Chemistry, 2020, 63, 4908-4928.	2.9	38
29	Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently. Cell Research, 2021, 31, 1315-1318.	5.7	37
30	Developing Equipotent Teixobactin Analogues against Drug-Resistant Bacteria and Discovering a Hydrophobic Interaction between Lipid II and Teixobactin. Journal of Medicinal Chemistry, 2018, 61, 3409-3421.	2.9	35
31	Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics. Nature Communications, 2019, 10, 3268.	5.8	32
32	Synthesis of Phosphaisoquinolinâ€1â€one by Annulation of Aryl Phosphinamides with Allenes through a Cobaltâ€Promoted Câ~H Functionalization. Asian Journal of Organic Chemistry, 2017, 6, 825-830.	1.3	31
33	Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation. Frontiers in Cell and Developmental Biology, 2021, 9, 685106.	1.8	31
34	Pd-Catalyzed sp2 C–H Hydroxylation with TFA/TFAA via Weak CoordinaÂtions. Synlett, 2013, 24, 2472-2476.	1.0	27
35	Synthesis of diverse heterocycles via one-pot cascade cross-dehydrogenative-coupling (CDC)/cyclization reaction. Organic Chemistry Frontiers, 2017, 4, 386-391.	2.3	25
36	Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2019, 62, 6561-6574.	2.9	25

#	Article	IF	Citations
37	FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice. Protein and Cell, 2020, 11, 534-539.	4.8	24
38	Discovery of an insulinâ€induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory elementâ€binding protein–mediated lipogenesis. Hepatology, 2022, 76, 1466-1481.	3.6	24
39	Synthesis, Evaluation, and Structure–Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation. Journal of Medicinal Chemistry, 2018, 61, 8693-8706.	2.9	23
40	One-pot synthesis of quaternary carbon centered cyclobutanes via Pd( $\langle scp \rangle ii \langle scp \rangle$ )-catalyzed cascade C( $sp \langle sup \rangle 3 \langle sup \rangle$ ) $\hat{a} \in H$ activations. Chemical Communications, 2017, 53, 1534-1537.	2.2	20
41	One-Step Synthesis of Diverse Pyridine-Containing Heterocycles with 3-Ethoxycyclobutanones at Room Temperature. Organic Letters, 2016, 18, 2304-2307.	2.4	19
42	A Preliminary Study of Diastereoselectivity in the Pd <sup>II</sup> â€Catalyzed C(sp <sup>3</sup> )â€H Alkoxylation of Cyclic Systems. Chemistry - A European Journal, 2016, 22, 3273-3277.	1.7	16
43	Mixing <i>O</i> -Containing and <i>N</i> -Containing Directing Groups for C–H Activation: A Strategy for the Synthesis of Highly Functionalized 2,2′-Biaryls. Journal of Organic Chemistry, 2018, 83, 2582-2591.	1.7	16
44	Synthesis of Quaternary Carbon-Centered Benzoindolizidinones via Novel Photoredox-Catalyzed Alkene Aminoarylation: Facile Access to Tylophorine and Analogues. CCS Chemistry, 2019, 1, 352-364.	4.6	10
45	CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses. Cancer Immunology Research, 2022, 10, 525-539.	1.6	7
46	Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity. IScience, 2021, 24, 103177.	1.9	6
47	Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. Antiviral Research, 2021, 194, 105161.	1.9	6
48	Design, synthesis and biological study of potent and covalent HER-2 tyrosine kinase inhibitors with low cytotoxicity in vitro. Chemical Papers, 2019, 73, 1333-1345.	1.0	4
49	Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells. Acta Pharmacologica Sinica, 2022, 43, 692-702.	2.8	4
50	PROTAC mediated FKBP12 degradation enhances Hepcidin expression via BMP signaling without immunosuppression activity. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	4
51	Design, synthesis, and biological evaluation of multiple targeting antimalarials. Acta Pharmaceutica Sinica B, 2021, 11, 2900-2913.	5.7	3
52	Editorial: Ubiquitin Code: From Cell Biology to Translational Medicine. Frontiers in Cell and Developmental Biology, 2021, 9, 791967.	1.8	1
53	Design and synthesis of water-soluble grifolin prodrugs for DNA methyltransferase 1 (DNMT1) down-regulation. RSC Advances, 2021, 11, 38907-38914.	1.7	0